Kiselak Tomas

CIK 00018301779 companiesWEST CONSHOHOCKEN, PA

SEC Profile

Transactions

Companies

Filings

CIK

0001830177

Recent Transactions

50 trades

Sale
Apogee Therapeutics, Inc.$APGE
Common Stock
2026-01-22$76.30/sh−1,750,000→ 298,647 total
Purchase
CRESCENT BIOPHARMA, INC.$CBIO
Ordinary Shares
2025-12-04$13.41/sh+1,360,000→ 2,747,866 total
Purchase
CRESCENT BIOPHARMA, INC.$CBIO
Pre-Funded Warrant (Right to Buy)
2025-12-04$13.41/sh+131,434→ 1,768,140 total
Purchase
Zenas BioPharma, Inc.$ZBIO
Common Stock
2025-10-07$19.00/sh+316,219→ 2,209,025 total
Award
Jade Biosciences, Inc.$JBIO
Pre-Funded Warrant (Right to Buy)
2025-10-06$9.14/sh+855,047→ 855,047 total
Award
Jade Biosciences, Inc.$JBIO
Common Stock
2025-10-06$9.14/sh+1,333,126→ 1,897,677 total
Award
Oruka Therapeutics, Inc.$ORKA
Common Stock
2025-09-17$15.00/sh+333,340→ 1,131,954 total
Award
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2025-07-01+21,000→ 21,000 total
Award
CRESCENT BIOPHARMA, INC.$CBIO
Stock Option (Right to Buy)
2025-06-23+9,023→ 9,023 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2025-06-17+14,461→ 14,461 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2025-06-17+14,461→ 14,461 total
Award
Zenas BioPharma, Inc.$ZBIO
Stock Option (Right to Buy)
2025-06-10+18,500→ 18,500 total
Award
Oruka Therapeutics, Inc.$ORKA
Stock Option (Right to Buy)
2025-06-02+17,500→ 17,500 total
Award
Spyre Therapeutics, Inc.$SYRE
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total
Award
Spyre Therapeutics, Inc.$SYRE
Stock Option (Right to Buy)
2025-05-29+25,000→ 25,000 total
Award
Jade Biosciences, Inc.$JBIO
Stock Option (Right to Buy)
2025-04-29+23,017→ 23,017 total
Exercise/Conversion
Oruka Therapeutics, Inc.$ORKA
Series A Non-Voting Convertible Preferred Stock
2024-11-19−160→ 0 total
Exercise/Conversion
Oruka Therapeutics, Inc.$ORKA
Common Stock
2024-11-19+160,000→ 798,614 total
Other
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2024-09-27−62,146→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series Seed Convertible Preferred Stock
2024-09-16−357,143→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series A Convertible Preferred Stock
2024-09-16−2,195,871→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series C Convertible Preferred Stock
2024-09-16−2,614,287→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+301,077→ 1,304,891 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+252,890→ 294,020 total
Purchase
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16$17.00/sh+300,000→ 1,604,891 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+709,794→ 1,003,814 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+41,130→ 41,140 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series B Convertible Preferred Stock
2024-09-16−6,163,236→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series Seed Convertible Preferred Stock
2024-09-16−357,143→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series A Convertible Preferred Stock
2024-09-16−2,195,871→ 0 total
Purchase
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16$17.00/sh+300,000→ 1,892,806 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series C Convertible Preferred Stock
2024-09-16−2,614,287→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+301,077→ 1,592,806 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+41,130→ 329,045 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+709,794→ 1,291,729 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Series B Convertible Preferred Stock
2024-09-16−6,163,236→ 0 total
Conversion
Zenas BioPharma, Inc.$ZBIO
Common Stock
2024-09-16+252,890→ 581,935 total
Award
Zenas BioPharma, Inc.$ZBIO
Stock Option (Right to Buy)
2024-09-12+37,000→ 37,000 total
Award
Zenas BioPharma, Inc.$ZBIO
Stock Option (Right to Buy)
2024-09-12+37,000→ 37,000 total
Award
Oruka Therapeutics, Inc.$ORKA
Common Stock
2024-09-11$23.00/sh+275,000→ 638,614 total
Award
Oruka Therapeutics, Inc.$ORKA
Series A Non-Voting Convertible Preferred Stock
2024-09-11$23000.00/sh+160→ 160 total
Award
Viridian Therapeutics, Inc.\DE$VRDN
Stock Option (Right to Buy)
2024-06-26+21,000→ 21,000 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2024-06-05+10,370→ 10,370 total
Award
Apogee Therapeutics, Inc.$APGE
Stock Option (Right to Buy)
2024-06-05+10,370→ 10,370 total
Award
Dianthus Therapeutics, Inc. /DE/$DNTH
Stock Option (Right to Buy)
2024-05-23+11,000→ 11,000 total
Award
Spyre Therapeutics, Inc.$SYRE
Stock Option (Right to Buy)
2024-05-14+11,323→ 11,323 total
Award
Spyre Therapeutics, Inc.$SYRE
Stock Option (Right to Buy)
2024-05-14+11,323→ 11,323 total
Exercise/Conversion
Spyre Therapeutics, Inc.$SYRE
Series A Preferred Stock
2024-04-25−90,992→ 346,045 total
Exercise/Conversion
Spyre Therapeutics, Inc.$SYRE
Common Stock
2024-04-25+3,639,680→ 4,018,101 total
Other
Dianthus Therapeutics, Inc. /DE/$DNTH
Common Stock
2024-04-01−58,857→ 0 total

Companies

Recent Filings

Address

200 BARR HARBOR DRIVE SUITE 400

WEST CONSHOHOCKEN, PA, 19428

View on SEC.gov